# Standard BioTools share price today (Standard BioTools Inc., LAB)

> Standard BioTools Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LAB · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/lab

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $0.61 (−49.2% in a year)
- P/E: 2.8×, against its own history
- Revenue (Jun 2026): $20.1 M (−7.6% on a year ago)
- Profit (Jun 2026), incl. one-off: −$26.8 M (one-off item, see below)
- Operating margin: −38.9% (+70.0 points on a year ago)
- ROE: −18%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Standard BioTools share price today? Standard BioTools Inc.'s share price was $0.61 at the close on 3 November 2026. That is 33.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $2, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 22 weeks running. Over the last 1 year the share price moved −54% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 5 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Standard BioTools pay? Standard BioTools Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Standard BioTools on? Standard BioTools is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Standard BioTools profitable? Standard BioTools Inc. posted a net loss of $26.8 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $74.9 M. That loss is 133.1% of the quarter's revenue. The same quarter a year earlier lost $33.5 M. 10 of the last 12 reported quarters were loss-making. Read this profit with care: at −$26.8 M it is bigger than the quarter's whole revenue of $20.1 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −38.9% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Standard BioTools make, and is it growing? Standard BioTools Inc. reported $20.1 M of revenue in the Jun 2026 quarter, −7.6% on the same quarter a year earlier. Over 4 years it has grown −10.1% a year on average. The last full year, FY25, came in at $85.3 M. The last four reported quarters add to $84.6 M. FY25 revenue was $85.3 M, −6.2% on the year before. Recent pace: the last four quarters grew −4.6% on average, against −10.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −4.8%, against −6.9% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Standard BioTools keep? Standard BioTools Inc.'s operating margin was −38.9% in the Jun 2026 quarter, 70.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between −109.3% and −51.7%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +70.0 percentage points on the year while gross margin changed +3.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Standard BioTools' profit turning into cash? Standard BioTools Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $74.3 M of cash, against −$74.9 M of profit. After $8.3 M of spending on assets, free cash was −$82.6 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Standard BioTools' cash go? Standard BioTools Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $19.5 M on assets over the last 3 years. Averaged over those years that is 7.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $19.5 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Standard BioTools' P/E ratio, and how does it compare with its own history? Standard BioTools Inc.'s P/E is 2.8×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Standard BioTools business getting better or worse? Standard BioTools Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Standard BioTools earn on its capital? Standard BioTools Inc. earned a ROE of −18% in FY25. That is up from a low of −83% in FY22. Its return on capital used (ROIC) is 18.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −87.8% net margin and 0.15× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −87.8% net margin × 0.15× asset turnover × 1.34× leverage (assets divided by equity) ≈ −17.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −7.7% − 11.2% = −18.9 percentage points. The 11.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Standard BioTools have too much debt? Standard BioTools Inc. has total debt of $28.1 M against shareholder equity of $540 M as of Jun 2026, so its debt is 0.05× its equity, which is very little. Year by year, that ratio went from 1.18 in FY21 to 0.07 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Standard BioTools shareholding pattern? 1.3% of Standard BioTools Inc.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 2.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Standard BioTools from balance-sheet trouble? For Standard BioTools Inc., the Z-score is 1.28. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.28 is inside the danger zone, so the balance sheet is a real risk. ## How does Standard BioTools rank in its industry? There is no score against its industry: Standard BioTools Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Standard BioTools compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Standard BioTools in size? Standard BioTools is the 70th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Treace Medical Concepts, Inc., Profound Medical Corp. and InfuSystem Holdings, Inc. Just below it: Electromed, Inc., TriSalus Life Sciences, Inc. and RxSight, Inc. ### Medical Devices companies close in size

1. [Treace Medical Concepts, Inc.](https://www.sectoralpha.in/us/stocks/tmci) $278 million
2. [Profound Medical Corp.](https://www.sectoralpha.in/us/stocks/prof) $255 million
3. [InfuSystem Holdings, Inc.](https://www.sectoralpha.in/us/stocks/infu) $255 million
4. Standard BioTools Inc. $240 million
5. [Electromed, Inc.](https://www.sectoralpha.in/us/stocks/elmd) $221 million
6. [TriSalus Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/tlsi) $214 million
7. [RxSight, Inc.](https://www.sectoralpha.in/us/stocks/rxst) $191 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Apartment Investment and Management Company](https://www.sectoralpha.in/us/stocks/aiv) $240 million · REIT - Residential
2. [Conduent Incorporated](https://www.sectoralpha.in/us/stocks/cndt) $240 million · Information Technology Services
3. Standard BioTools Inc. $239 million
4. [Pitanium Limited](https://www.sectoralpha.in/us/stocks/ptnm) $239 million · Household & Personal Products
5. [Immersion Corporation](https://www.sectoralpha.in/us/stocks/immr) $239 million · Software - Application

## What else do people ask about Standard BioTools? ### What were Standard BioTools's latest quarterly results? Standard BioTools Inc. reported revenue of $20.1 M and a net loss of $26.8 M for the Jun 2026 quarter. Earnings per share were −$0.07. The operating margin was −38.9%, 70.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Standard BioTools's market cap? Standard BioTools Inc.'s market capitalisation is $240 M at a stock price of $0.61. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Standard BioTools performing? Standard BioTools Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 22 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Standard BioTools's stock price go up? This page does not forecast Standard BioTools Inc.'s stock price. What it shows instead: the stock price is $0.61. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Standard BioTools in its business cycle? Standard BioTools Inc.'s FY25 operating margin was −109.3%, against a 5-year range of −109.3% to −51.7%: the low end of its own range, which is often where recoveries start. The latest quarter was −38.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Standard BioTools story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Standard BioTools a stock worth studying right now? What the numbers show: Standard BioTools Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.